top of page icon
MicroTransponder Inc.

The Serenity System™ is being developed by MicroTransponder to treat tinnitus. The Serenity System™ pairs an existing therapy called Vagus Nerve Stimulation (VNS) with listening to tones. VNS is approved by the FDA and has been used to treat over 60,000 patients for epilepsy and depression, but has not yet been evaluated for safety or efficacy to treat tinnitus.

Nasseo, Inc nasseo logo

Nasseo, Inc. ("Nasseo") is a medical device company that is dedicated to providing clinicians and patients with better dental and orthopedic implant treatment options.

Natural Dental Implants AG

Natural Dental Implants™ AG (Dallas, TX and Berlin, Germany based) is an early-stage dental technology and services company with a disruptive technology – the Replicate™ Non-Surgical Tooth Replacement System. It replaces non-functional teeth with anatomiCally shaped prostheses rather than surgical dental implants. The Replicate Non-surgical Tooth Replacement System(TM) may be used as an alternative to three unit dental bridges and single tooth dental implants. Patients benefit from fewer visits to the dentist and general dentists benefit by performing implants themselves, rather than referring out to a specialist.

*Investigational Device, Not for Sale in the United States, limited by Federal law.


Dignitana develops a patented scalp cooling system, DigniCap® that reduces chemotherapy-induced hair loss. Dignitana's patented DigniCap® system has demonstrated excellent scientific results in clinical studies. More than eight out of ten treated patients were able to retain enough of their hair to eliminate the need for a wig.


InterVene Inc is developing the first non-implantable, catheter-based therapy to restore valvular competency in patients with chronic venous insufficiency (CVI) in the deep veins - a disease that causes painful venous stasis ulcers. The therapy is based on a proven open-surgical predicate procedure (The Maleti Neovalve), in which new valves are created out of the patient’s native vein wall tissue. InterVene's minimally invasive approach will open up an enormous new segment of the CVI market, by transitioning the strategy of care from costly, chronic, disease management to curative intervention.

Ortho Kinematics Inc.

Ortho Kinematics, Inc. is a spine diagnostics company focused on spine motion analysis products and services. Ortho Kinematics has developed the KineGraph Vertebral Motion Analyzer, which uses fluoroscopy to capture the spine in motion to produce patient-specific graphs of the kinematics for each vertebral level.

Semler Scientific Semler Scientific logo

Semler Scientific is an emerging medical risk-assessment company. Their mission is to develop, manufacture and market patented products that identify the risk profile of medical patients to allow healthcare providers to capture full reimbursement potential for their services.

Socrates Health Solutions

Improving the lives of diabetics through non-invasive blood monitoring


Admittance has developed CardioVol™, which interrogates the heart with electric fields using existing pacemaker leads and, in real time, provides blood volume data including relative stroke volume.


AlgoMedica has developed a medical imaging technology that allows for the reduction of radiation dosage.

PureDiscovery Brainspace

PureDiscovery Brainspace is the first post-search software platform for semantiCally connecting the enterprise.


Validic is the mobile health’s industry premier technology platform for accessing data from mobile health devices, wearable, in-home devices and patient healthcare apps.


Kickbox ensures you only send email to real users and helps you separate the low-quality addresses from high-value contacts. Protect your reputation, increase open rates, and save money with Kickbox.

Channel Medsystems

Innovative, office-based cryothermic treatment for heavy menstrual bleeding due to benign causes.

Maui Imaging

With their proprietary technology, Maui Imaging will revolutionize medical imaging. Their solution enables access to high resolution imaging via an affordable, safe, and portable system in anticipation of the financial and throughput demands of national healthcare systems.


RETROTOPE is a privately held company focused on the development of ways of controlling metabolic processes associated with the oxidative stress conditions. Areas of interest include age-related diseases. RETROTOPE uses isotope effect to slow down damaging pathways. The company has several discovery and development programmes that involve major classes of biopolymers, with the major focus in neurological diseases such as Friedreich's ataxia.

Silicone Arts Laboratories, LLC

Silicone Arts Labs develops synthetic skin products for cosmetic and medical uses, offering superior concealment in a topical application. The leading product, Dermaflage, uses a thin layer of translucent silicone to replicate the unique tone and texture of the user’s skin – unlike anything on the market today.

Cancer Gene Connect

Cancer Gene Connect is a hereditary disease risk assessment platform originally developed by UT Southwestern.


PerioSciences researches, formulates, and markets topiCally applied, antioxidant-based oral care and oral hygiene products. Founded in 2008 and headquartered in Dallas, Texas, PerioSciences has established a new category of products – antioxidant-based oral care. PerioSciences is committed to world-class research and to providing the most advanced products for oral health. Using a state-of-the-art business model, PerioSciences partners in sales and distribution with dental professionals, hygienists, and specialists as well as and other medical professionals and medi-spas.

Savara Pharmaceuticals

Savara is an emerging specialty pharmaceutical company developing innovative pulmonary drugs for the treatment of serious and life-threatening conditions that are inadequately treated with currently available medicines. The company’s lead product, AeroVanc™ (vancomycin hydrochloride inhalation powder), addresses an unmet clinical need in the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in patients with cystic fibrosis (CF). AeroVanc is an inhaled dry powder form of the antibiotic vancomycin in a capsule-based inhaler designed for convenient self-administration. AeroVanc has demonstrated positive safety and tolerability results in a Phase I clinical study conducted in healthy subjects and patients with cystic fibrosis, and Savara is in preparation to initiate a Phase II clinical study.


In 2007, founder Holly Thaggard created the first line of advanced UV protective sunscreens with a singular purpose: to prevent sun damage 365 days a year and to say goodbye to the bad stuff, like parabens, petrochemicals, and fragrances. Supergoop! has since grown into a family of highly-technical skincare solutions, using the most powerful antioxidants and scientific ingredients that protect, combat the signs of aging, and promote healthier, youthful skin.


Vapogenix Inc. is an early stage company focused on developing novel, non-opioid analgesics for acute and chronic pain management. Vapogenix's licensed technology covers novel formulations of known medications through new routes of administration for new indications, with the aim of creating potent analgesic and anti-inflammatory drugs. The company’s lead product, VPX-595, is a compound being developed initially for the treatment of acute pain.

Lantern Pharma

Lantern Pharma is leading a wave of innovation in cancer treatment that we believe will bring the best therapies to patients who are most likely to respond. We are pioneering precision medicine approach to cancer by tailoring promising drug programs to the right patients. Our approach is to use biomarker based genetic screening to identify and treat patients that would benefit most from our drugs. We believe this approach will reduce the cost of development and increase the speed to market. Our strategy is to acquire or partner with promising drug and diagnostic companies to move forward promising personalized medicine programs for cancer patients.